Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor.
Zhang, C., Ibrahim, P.N., Zhang, J., Burton, E.A., Habets, G., Zhang, Y., Powell, B., West, B.L., Matusow, B., Tsang, G., Shellooe, R., Carias, H., Nguyen, H., Marimuthu, A., Zhang, K.Y., Oh, A., Bremer, R., Hurt, C.R., Artis, D.R., Wu, G., Nespi, M., Spevak, W., Lin, P., Nolop, K., Hirth, P., Tesch, G.H., Bollag, G.(2013) Proc Natl Acad Sci U S A 110: 5689-5694
- PubMed: 23493555 
- DOI: https://doi.org/10.1073/pnas.1219457110
- Primary Citation of Related Structures:  
4HVS, 4HW7 - PubMed Abstract: 
Inflammation and cancer, two therapeutic areas historically addressed by separate drug discovery efforts, are now coupled in treatment approaches by a growing understanding of the dynamic molecular dialogues between immune and cancer cells. Agents that target specific compartments of the immune system, therefore, not only bring new disease modifying modalities to inflammatory diseases, but also offer a new avenue to cancer therapy by disrupting immune components of the microenvironment that foster tumor growth, progression, immune evasion, and treatment resistance ...